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CARBIMAZOLE (2 Carbethoxy-thio-1-methyl glyoxaline) was first introduced by
Lawson, Rimington, and Searle (1951). Early reports by Lawson and Barry
(1951), Macgregor and Miller (1953), Doniach (1953) and Poate (1953) stressed
the freedom from toxicity and potency of carbimazole as an anti-thyroid drug.
Though potent, thiourea derivatives had proved to have a significant toxic risk.
For this reason, most recent workers have concentrated on a comparison of
carbimazole with thiourea drugs in regard to studies of toxicity. McGavack,
et al. (1956), in describing their experiences in forty-one cases with special
reference to speed of control of symptoms, remark on the sparsity of reports of
clinical experience with carbimazole.
The purpose of the present paper is to record observations made in a group
of thyrotoxic patients concerning short- and long-term effects and drug toxicity.
An assessment of the place of carbimazole in treatment and factors which may
influence the response of thyrotoxic patients to the compound are recorded.
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Fig. 1-Distribution according to sex and age in 60 thyrotoxic patients.
148METHODS AND PLAN OF STUDY.
Sixty non-selected patients were studied, comprising 52 female and 8 male
patients, of age ranging from 17-74 years. The distribution according to age, sex,
and gland type is shown in Fig. 1. Symptoms were present for from 12 days
to 3 years (average 11 months) at the time of first attendance. The average
duration of symptoms before attendance for smooth toxic goitre was 7 months
and for nodular goitre 10 months. Sixty-six per cent. of patients attended within
6 months and 82 per cent. within a year.
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Fig. 2-Incidence of degrces of exophthalmos as a percentage of gland type.
The type and degree of thyroid enlargement were assessed clinically on each
visit. A smooth goitre was noted in 33 patients, nodular gland in 20, and in 7
patients no clinical enlargement was demonstrable (Not +).
Eye changes were judged clinically in 3 grades, the least marked being a
thyrotoxic stare with lid lag and the most severe indicating marked exophthalmos
with or without ophthalmoplegia. Moderate grades fell between these two
,149extremes. The incidence of eye changes related to the gland type is shown in
Fig. 2. There were eye signs in 50 per cent. of the 60 patients.
The diagnosis of thyrotoxicosis was made clinically with confirmation in 34
patients by 131 uptake and by basal metabolic rate estimation in 3 cases. Serum
cholesterol was assessed at the first attendance in 15 patients. In 3 the result was
200 mg./100 ml. or more and in the remainder averaged 167 mg./100 ml.
All patients were started on carbimazole 30 mgs. to 45 mgs. daily in three doses.
L-thyroxine-sodium 0.1-0.3 mg. was given concurrently with the dosage of
carbimazole to reduce the risk of goitrogenesis (Astwood, et el., 1943; Purves,
1943; Fraser, et al., 1954) and to avoid aggravation of eye signs (Fraser and
Wilkinson, 1953).-
Throughout the investigation, the patients were examined at intervals of 1-3
months, the attendances being at approximately the same time on each occasion
in relation to meal times. As far as possible, each was weighed in the same attire
on each attendance. Routine differential and total white cell counts were under-
taken on each visit. The decision as to when each patient was euthyroid was
assessed clinically.
All patients treated medically had at least 12 months' treatment and varied on
average between 14-16 months. Carbimazole was gradually withdrawn, the dose
in most patients being reduced to 5 mgs. daily, followed by 5 mgs. on alternate
days, without added thyroxine in the last few months of treatment. Supervision
has been continued up to 30 months after stopping carbimazole.
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Fig. 3-Time required in gland types for establishment of a cuthyroid state.
150RESULTS.
1. The Anti-Thyroid Effect.
Most patients on carbimazole 15 mgs. three times daily with 1-thyroxine sodium
0.1 mg. twice daily reported an improvement in symptoms in 2-4 weeks. The
establishment of a clinically assessed euthyroid state took much longer. For
smooth goitres, 2-17 months (average 6 months) was required, for nodular goitre
3-17 months (average 8 months), and where the gland was not palpable 4-14
months (average 7 months) was necessary. Resistant cases are excluded from
the above assessments.
Sixty-two per cent. of the patients with smooth goitres were euthyroid in
6 months as compared with 43 per cent. with nodular glands. Fig. 3 shows the
time taken for a euthyroid state in relation to the gland type and the outcome
of carbimazole treatment in the total series is shown in Table 1.
TABLE 1.
ANALYSIS OF CARBIMAZOLE TREATMENT IN 60 THYROTOXIC PATIENTS.
GLAND TYPE OUTCOME OF CARBIMAZOLE % OF TOTAL
TREATMENT Smooth Nodular Not + Total
Elective Surgery - - 6 ... 3 ... - ... 9 ... 15
ElectiveI131 - - - 2 ... 1 ... - ... 3 ... 5
Toxic Response - 2 ... ... - 2 ... 3
Resistance to the drug - - ... 2 ... - ... 2 ... 3
Still on treatment - - 2 ... 2 ... - ... 4 ... 7
Definitive Carbimazole-
Remissions - - 16 ... 4 ... 5 ... 25 ... 42
Relapses- - - 5 ... 8 ... 2 ... 15 ... 25
TOTAL - - 33 ... 20 ... 7 ... 60 ... 100
Of the 60 patients, carbimazole was used as a preliminary to an elective
operation in 9 cases (15 per cent.)-6 smooth and 3 nodular-and as a preparatory
treatment to radioactive iodine in 3 cases (5 per cent.)-2 smooth and 1 nodular.
One patient was treated by sub-total thyroidectomy on account of granulopenia
while another required treatment with radioactive iodine for agranulocytic
angina. Of the remaining 46 cases, 2 showed resistance to the drug. One of these
has received 45 months' treatment and is still toxic, requiring high dosage, while
the other has had 39 months' adequate treatment with incomplete control. Four
patients are still on treatment, 19 months, 22 months, 23 months, and 34 months
at the time of reporting. They are reasonably well controlled while on the drug.
The remaining 40 patients (67 per cent.) proved amenable to treatment with
carbimazole. Twenty-five (62.5 per cent.) of these have had remissions following
cessation of treatment for from 5-30 nmonths (Table 2). Fifteen cases (37.5
per cent.) have relapsed. The time following treatment at which relapse occurred
151TABLE 2.
ANALYSIS OF REMISSIONS AND RELAPSES IN 40 PATIENTS
FOLLOWING CARB1MAZOLE THERAPY.
MONTHS AFTER SMOOTH CASES =21 NODULAR CASES = 12 NOT + CASES=7 CESSATION OF TOTAL
CARBIMAZOLE Rem. Rel. Rem. Rel. Rem. Rel.
0-6 ... 2 ... 2 ... 1 ... 6 ... I ... 1 ... 12
7-12 ... 5 ... I . 2 ... - . .. . .. 1 ... 10
13-18 ... 5 ... ... I ... I ... ... I ... 8
19-24 ... 2 2 ... - ... 1 ... 1 ... - ... 6
25-30 ... 2 ... 5 ... 4 ... 8 ... 2 ... 2 ... 4
0-30 ... 16 ... 5 .. 4 ... 8 ... 5 ... 2 ... 40
% of gland type
fully treated - 76 ... 24 ... 33 ... 67 ... 71 ... 29 ...
Total remissions in 40 selected cases=25 (62.5%).
Total remissions in 60 unselected cases=25 (42.0%).
Rem.=Remissions. Rel.=Relapses. Not + =Thyroid not enlarged.
is shown in rable 2. Of the 21 patients with smooth goitres treated on
carbimazole, there has been a remission for from 5-30 months in 16 (76 per cent.).
The corresponding figure for nodular goitre was 33 per cent. Patients without
thyroid enlargement numbered 7. Of these, 5 (71 per cent.) have remained
euthyroid on stopping the drug. The rate of remission of the total 60 unselected
patients has been 42 per cent.
Of the relapsing cases, 53 per cent. of all failures have occurred in the first
6 months and 67 per cent. within a year. Seventy-five per cent. of the relapses
affecting nodular glands were detected within 6 months.
2. Effect on the Eye Signs.
Of the 60 patients, eye signs were observed in 31. They occurred with about
equal frequency and severity in the gland types (Fig. 2). A thyrotoxic stare was
present in 6, while there was moderate exophthalmos in 21 and severe eye changes
in 4. The eyes were normal in the 29 remaining cases. Table 3 shows the effects
of treatment on the eye signs. In 36 patients (60 per cent.) the eyes were un-
changed, in 19 (31.5 per cent.) there was improvement, and in 5 (8.5 per cent.)
the exophthalmos was aggravated. All these last cases constituted relapses or cases
unsuited to medical treatment alone.
Of the 4 patients with severe exophthalmos, 2 had ophthalmoplegia. Both
showed some improvement in the eye signs on carbimazole. In one of the re-
maining cases the exophthalmos remained unchanged in spite of clinical remission
of the disease process. In the other the eye signs became worse because treatment
was carried out irregularly. This patient was elderly, had a small nodular gland,
and was treated electively by radioactive iodine.
152OF ~~TABLE 3.
ANALYSIS O CHANGE OF EmE SIGNS IN 60 THYROTO0XIC PATIENT'S
ON CARBI MAZoLE.
TrRF,ATMIENT EYE SIGNS. IN -SIXTY CASES
CATEGORY UNCHANG.ED IMPROVED WORSE,
ON
CAMUIMAZOLE Sm.1:: Nod. Not + Total,% Sin. Nod. Not + Tot.Al % Snin. Nod. NQt + Total O
Remissiqn§ - 12 ... 2 .. .4 ... 18(72).. 4 .. .. .. 7(28%) ....-.....
Relapses -2 ... 4 ... I .. 7(47%,) ... 3 *.3' ... ... 6(40% ..-.. . 1.23%
Elective
Surger-y .-4 . 2 .. -.. 6(67%/).. 2 ... ..- ... 2(220/), M. . ..-..11%)
Ellective
111 - 2 ... ... - 2. 2(67%/,) ... - .. - . . .... ..1... ... ... 1(33%/,)
Remaini.ng
Cases -3 3. . . 3(37.5%)... ... 4 ...
. ... 4( 0) 0...o 1...; ... 1(12.5%)
TotalCases- 23 ..8 ...5 .36,(69%) . 9 . 9 .. ..A9 -931.5). 1 .3.. * 1 .5(8.5%)
Sm. Smooth. Nod. Nodular. Not + =Thyroid not cnlargedf
TABLE 4.
ANALYSIS OF_ CHANGE IN GLAND SIZE IN 60 TIHYROTOXIC PATIENTS
ON CARBIMIAZOLE.
TREAT'MENT GLAND SIZE IN SIXTY CASES
CATEGORY' UNCH4ANGED DECREASED INCREASED
ON
CARaIMAZOLE Sml. Nod. Not + Total % Sm'. Nod. -Not + Total 0/' SM. Nod. Not + Total
Remissions- 5 ... 2 ... 5 ... 12(48%/).. 11 ...2 ... -..13(52%).. .
Relapses - 3 ... 6 ... 1 ... 10(67%).. ... 2 2. 4 . 4(27%).. ... . . ... 1(6%)
Electivc
Surgery I ... 3 ... . ... 4(44%) .. ..-..-.. - ..5 ...- ..- ... 5(56%)
E-lective
I131 -1..1... . ... 2(67%).. -..-..-. - ..I... ... .. ... 1(33%)
Remainiing
Cases -4 ... 2 6. . 6(75%). - . 2 2; . 2(25%) ...
. ...- - -
Total -14 ... 14 ...6 .34(57%) ... 13 ... 6 ... ...19(32%) ... 6 ... . ... 1 7(11%)
Sm.=Smooth, Nod. Nodular. Not + =Thyroid,not enlarged.
1533. Effect on Gland Size anzd Consistenzcv at Operation.
The outcome of carbimazole therapy on gland size was noted in all 60 patients
(Table 4). The gland was unchaniged in 34 (67 per cent.), decreased in size in
19 (32 per cent.) and increased in 7 (11 per cent.) A decrease in gland size was
more common in remitting cases-52 per cenit. as compared with 27 per cent.
in relapses. No case in which the gland increased in size showed a remission.
Surgery was decided on in 5 patients because of the size of the gland on first
interview or because of its rapid enlargement in the early stages of carbimazole
treatment. All had smooth glands and varied in-age from 20-53 years. In 4 others,
surgical treatment was considered necessary at the first attendance on account
of other factors such as nodularity, age, and mechanical effects. Toxicity was
adequately controlled in all 9 patients pre-operatively.
Four patients were treated by sub-total thyroidectomy on account of relapse
after adequate duration of treatment. One operation wvas necessitated by
granulopenia complicating carbimazole treatment.
In all, 14 sub-total thyroidectomies were required. Lugol's iodine 5 minims
three times daily was given in the 10-14 days before operation concurrently with
carbimazole. In all patients the gland was enlarged and vascular. In no instance
was it considered friable and no difficulty from bleeding at operation was
encountered.
4. Effect on Body Weight.
Weight gain was a constant feature in all cases, though there was great variation
in the amount, which varied from 3 lb. to 42 lb. and expressed as a percentage
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Fig. 4-Percentage weight gain according to gland type.
154of the patient's weight on the first attendance was 2 to 33. The average weight
gain in cases which remitted was 12.6 lb. (9 per cent.) and in relapsed cases
15.4 lb. (12 per cent.). Fig. 4 shows the weight gain per cent. related to the gland
types. This shows no significant difference in the average weight gains in cases
with smooth, nodular or "not enlarged" glands. For the cases going to operation
the average weight gain was 9 per cent.
Considering the two resistant cases, both with nodular glands, one had a weight
gain of only 3.5 per cent. in 36 months while the other gained by 18 per cent.
over 29 months.
5. Effect on Associated Pregnan'y.
Three patients in the series were pregnant. The first became pregnant during
the early stages of carbimazole treatment, and treatment was continued throughout
the pregnancy without incident. Four months after completing a 16-months'
TABLE 5.
ToxiC AND ASYmPTONIATIC LEUCOPENIC REACTIONS IN 60 THYROTOXIC PATIENTS
ON CARBIMAZOLE.
AT ONSET
SEX AND Daily DIAGNOSIS AND
CASE AGE Dosage Stage of CLINICAL FEATURES PERCENTAGE
No. YEARS mgms. Treatment INCIDFNCF
46 ... F. 58 ... 45 ... 22 days ... Agranulocytic Angina. \ Blood Dyscrasia
W.C.C. 3,60J N. 22% 1.5%
5 ... F. 74 ... 45 ... 60 days ... Allergic Stomatitis.
Contact Dermatitis. A
28 ... M. 43 ... 45 ... 10 days ... Allergic Erythema. Allergic Reacti'ons
35 ... F. 33 ... 45 .. 14 days ... Erythematous rash. 4.5%
W.C.C. 3,200 N. 49% J
I
... F. 54 ... 5 ... 12 months ... No symptoms.
W.C.C. 3,100 N. 42%
4 ... F. 53 ... 15 ... 5 months ... No symptoms.
W.C.C. 1,000 N. 65%
7 ... F. 54 ... 45 ... 5 months ... No symptoms. I
W.C.C. 2,800 N. 48% Asymptomaric
9 ... F. 61 ... 45 ... 3 months ... No symptoms. t..Leuopeni
W.C.C. 3,900 N. 47%
13 ... F. 38 ... 45 ... 1 month ... No symptoms. 105°
W.C.C. 3,600 N. 63% 1.5
27 ... F. 17 ... 45 ... 2 months ... No symptoms.
W.C.C. 2,700 N. 48%
30 ... F. 59 .. 30 ... 5 months... No symptoms.
W.C.C. 3,100 N. 58%
No patient had a history of previous allergy.
Treatment was continued with carbimazole in all except patients Nos. 46 and 35.
155course of treatment pregnancy occurred again. She appeared to have undergone
remission, no further carbimazole was given and there was no relapse during or
immediately following the pregnancy. However, 19 months later she showed
slight recurrence of- thyrotoxicosis and was treated, by sub-total thyroidectomy.
The second patient was pregnant in the last 6 imonths of carbimazole therapy.
Mother and child did satisfactorily and the patient is now euthyroid 15 months
following a course of carbimazole lasting 19 months.
'h'The' third patient became pregnant 3 months after starting treatment. By the
third month of pregnancy control was unsatisfactory, the thyroid enlarged
rapidly and she had definite exophthalmos. She was treated by sub-total
thyroidectomy. and is now euthyroid 17 months' later. No cye changes are
evident.
6. Toxic Effects.
One patient with agranulocytic anginia, 3 with allergic responses, and 7 with
asymptomatic leucopenia were observed (Table 5), viz. -
One female patieit of 58 years (Case 46), with a slight smooth goitre, developed
a sore throat on the twenty-second day of treatment. The white cell count fell
to 3,600 per c.mm. with neutrophil polymorphs 22 per cent. Carbimazole was
promptly omitted with subsidence of symptoms. She was successfully treated by
radioactive iodine and is now euthyroid some 3 years later.
One patient (Case 5) complain'ed of a sore tongue and mouth after 2 months'
treatment'with carbimazole. The lesion was!allergic in type and readily subsided
with local,application of neomycin and hydrocortisone solution. There was no
associated blood dyscrasia.
After 7 months of tteatment the same patient developed a contact dermatitis
to carbimazole tablets affecting the, left index finger and thumb. This settled
spontaneously when she used a spoon for removing the tablets from the jar.
A 43-year-old male patient (Case 28) developed an itchy red rash with "prurigo
nodules" ten days after starting treatment. The rash, mainly on the trunk and
upper limbs, continued for' i Aionth and cleared without interruption of
carbimazole therapy. There was a recurrence of the rash six months later. This
responded satisfactorily to an anti-histamine drug.
A further patient (Case 35'), a 33-year-old woman, also developed a generalised
erythematous rash with a leucopenia of 3,200 per c.mm., neutrophil polymorphs
49 per cent. two weeks after' st'r'ting carbimazole. The drug was withdrawn, and
she was satisfactorily treated surgically.
'Seven'patients were noted on routine white cell counts to have leucopenia.
There were no associated symptoms-and carbimazole treatment-was continued
with no ill effects. The figures for white cell counts are shown in Table 5.
Grouping Case 35 as an allergic response, serious blood dyscrasia arose in 1.5
per cent. of cases and- simple allergic -reaction in 4.5 per--cent-;- Asympt-omatic
leucopenia was simply a"a chance-routine finding, the blood count returning to
a low normal value 1-2.weeks later. The incidence was 10.5 per cents,
156TABLE 6.
iSUMM1NARY OF PAIRS OF FACTORS PLOTTED ON SCATTER DIAGRAMS.
NUMBER OF
SUBJECrS X y
60 ... Age in years ... Duration of symptoms in months
33 ... Age in years ... 1131 "T" factor
30 ... Weight gain with treatment as %/,
of initial weight in lbs. ... 1131 "T" factor
50 ... Weight gain with treatment as %
of initial weight in lbs. ... Initial weight in lbs.
50 ... Actual weight gain in lbs. with
treatment Initial weight in lbs.
27 ... Actual weight gain in lbs. with
treatment ... Duration till euthyroid in months
50 ... Weight gain with treatment as %
of initial weight ... Duration till cuthyroid in months
11 ... Weight gain with treatment ... Stage of relapse in months
34 ... Weight gain with treatment as %
of ideal weight ... Total carbimazole till euthyroid in gms.
15 ... Total duration of treatmcnt in
months ... Stage of relapse in months
No apparent relationship demonstrated.
DISCUSSION.
The potency of a new anti-thyroid substance may be tested by its blocking
effect oni the uptake of 1131 by the normal human thyroid (Stanley and Astwood,
1947) or by a similar effect on the thyrotoxic gland (Stanley and Astwood, 1948).
Macgregor and Miller (1953), while demonstrating a more potent effect from
carbimazole as compared with methimazole in doses as small as 0.5 mgm., using
the former technique, stress the caution necessary in transferring the results of
potency trials of this type into the clinical field. Doniach (1953) remarked on
the fact that such tests do not take into account the cumulative properties of the
drug, the individual response to dosage, and the amount of hormone stored in the
gland. The same remarks apply to tests of inhibition in vitro of the enzymic
oxidative iodination of protein (Fraser, et al., 1954). Only by clinical trial can
the place of an anti-thyroid substance in treatment and its toxic risk be estimated.
1. Anti-Thyroid Effect.
The decision as to when a euthyroid state has been achieved is a difficult one
in most patients. In the present series 6-8 months were necessary for maximum
improvement as judged by return to normal of the pulse rate, sweating, tremor,
and other signs. In reports from the literature, control is claimed to have been
achieved much earlier. McGavack, et al. (1956), in 38 patients treated on 30-60
mgm. of carbimazole daily obtained control of thyrotoxic features in 21-84 days
(average 35 days), while Kirkeby and Romcke (1955) found toxic symptoms
157to cease in 3-12 weeks and Bartel (1953) in an average of 8 weeks. There is
no doubting that very considerable improvement was noted in the initial 2 months
in all patients treated. No comparable studies of carbimazole combined with
thyroxine are available, but in the series of 32 patients treated on methyl thiouracil
with thyroxine, Fraser and Wilkinson (1953), a euthyroid response was achieved
in 6-8 weeks. Using carbimazole alone, Doniach (1953), in 90 patients with
clinical and B.M.R. control, found a return to a euthyroid state in 2-8 weeks
in 72 subjects while 18 cases responded slowly, requiring 3-6 months. She
considered these slow responses due to such factors as insufficient dosage and
associated psychological stress, and noted a high proportion of elderly patients
with small nodular glands among the resistant subjects. She further postulated
in some instances of resistance that such patients might detoxicate or excrete the
drug rapidly and so require a higher dosage.
None of these factors appears to be operative in the present series and the slow
development of euthyroidism can be accounted for only by different criteria of
assessment for in all cases the patient had to satisfy the most meticulous criteria
of normality before being judged euthyroid, special attention being paid to
absence of tremor and sweating, coupled with the return of normal energy, a
normal resting pulse rate and maximum weight gain.
In regard to the resistant cases in the present study, one was a man of 43 years
who required 36 months of treatment before toxicity was controlled, the other
a 39-year-old woman who became euthyroid only after 29 months. Both had
moderately enlarged nodular glands, and had carbimazole 45 mgm., and at times
60 mgm., with 1 thyroxine 0.1 mgm. twice daily with only partial control.
Hernberg and Lamberg (1957) record 4 cases out of 81 in whom not even a
primary response occurred on "thyrostatic drugs." The reason for these resistant
cases is not clear.
2. Effect on Eye Signs and Gland Size.
Eye signs were not noted so frequently in this series as in that of Doniach
(30 in 60 cases as compared with 63 in 90 cases). Only 3 patients had aggravation
of eye signs as compared with 5 in the present series. Goitrogenesis in the present
study had an incidence of 11 per cent. as compared with 6 per cent. in that of
Doniach. Neither the effect on the eye signs nor the goitre appear to particularly
comnmend the routine addition of thyroxine to treatment. It must be noted,
however, that Doniach's was a very closely controlled group of patients. In
routine out-patient management, the intervals between attendances for adjustment
of dosage may be longer and marked aggravation of eye signs and gland size
might arise from overdosage. In support of this, Fraser, et al. (1954), in 113
patients treated on methimazole and carbimazole with added thyroxine found no
aggravation of eye signs nor any instanice of goitrogenesis.
3. The Incidence of Remission.
In this series the rate of 62.5 per cent. for remissions of from 5-30 months for
all gland types treated definitively with carbimazole compares very well with
any results so far reported for other thyrostatic drugs. Hernberg and Lamberg
158report a 25 per cent. remission rate following mixed anti-thyroid treatment in
85 patients, 60 of which had noclular glands. Of the smooth gland patients, their
remission rate of 73.8 per cenit. is very similar to that of the present group (76
per cent.). Other studies on results obtained with long-term treatment with
propyl thiouracil are those of McCullagh and Cassidy (1953), who reported a
remission rate of 66.7 per cent. in 60 patients with smooth goitre 4 years after
stoppinig the treatment, and of Iversen (1951, 1955), who reported a 79.6 per cenlt.
remissioni rate in a series of 144 patients treated on methyl thiouracil. Similarly
Aspenstrom (1953), usinig propyl thiouracil, observed remission in 75 per cent.
of subjects with smooth goitre and 65 per cent. of those with nodular glands.
4. Toxic Reactions.
Several papers deal with the low incidence of toxic complications of carbimazole
as compared with other thvrostatic drugs. Doniach (1953) reported absence of
toxicity in 150 patients. Bartel (1953), in a series of 52 cases, described 2 patielnts
with skin rashes and 1 with agranulocytic angina; an incidence of 6 per cent.
total or 2.0 per cent. of serious reaction. The agranulocvtic patient had a white
cell count of 2,000 per c.mm. with no polymorphonuclear cells. Fraser, et al.
(1954), in 57 patients on carbimazole had one instance of agranulocytosis in a
patient who had previously suffered from skin and joint symptoms with
nmethimazole. Ihe reaction to carbimazole arose 5 weeks after changing to this
drug. rhe white cell count fell to 2,000, polymorphs 3 per cent., and returned
to normal in 10 days. Harrison (1954) and Shaw (1955) each recorded a case
of agraiiulocytosis on carbimazole with recovery. Greene and Morgan (1956),
in a series of 181 patients, found 4 with harmless rashes in whom treatment could
be continued. Two patients developed purpura, 1 pretibial myxaedema, and 1
pure red cell anaemia, all necessitating treatment by sub-total thyroidectomv. This
represented an incidence of serious side effects in 0.6 per cent. By summation
of the 435 cases reported at that time, they noted the occurrence of rashes in
1.6 per cent., agranulocytosis in 0.7 per cent., and pancytopenia and pure red cell
anaemia in 0.1 per cent. each. The total toxic reaction of 3.4 per cent. compares
favourably with that for methyl thiouracil quoted by Greene and Morgan (1956)
as 5.8 per cent. Burrell, et al. (1956), reported on 1,046 cases regarding toxicity.
The incidence of major toxic reactions (marrow aplasia, fever, lymphadenopathv
and arthralgia) was 0.5 per cent. and minor reactions (rashes, nausea, headache,
etc.) in 1.5 per cent. The first fatal case of marrow aplasia arising with
carbimazole treatment was described by Richardson, et al. (1954). Further fatal
cases have been published by Burrell (1956) and Tait (1957).
In the present series, one case of agranulocytic angina was encountered,
representing an incidence of 1.5 per cent. In view of the small number of patients
studied, this figure is probably an exaggeration of the true risk. The same applies
to the development of minor allergic complications, the occurrence of generalised
rashes in this series in 4.5 per cent. being rather higher in incidence than elsewhere
reported. I have so far not found any previous account of contact dermatitis
to the carbimazole tablet such as arose in one case in this series.
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c5. Factors influencing Response to Treatment.
All investigators agree that carbimazole is an effective anti-thyroid agent with
a definite, but slight toxic risk. Except for the rare resistant cases cited above, all
patients with thyrotoxic glands will be controlled by the drug whether the
eventual treatment is by thyroidectomy, radioactive iodine or the patient be
continued on definitive drug treatment.
In the last group of patients, certain factors undoubtedly influence the
therapeutic response. Among the most important are age and gland type.
Remissions and relapses expressed as a percentage of the gland types in relation-
ship to age groups are shown in Figs. 5 and 6 respectively. Fifty-one per cent.
of the remissions up to the age of 40 years involve smooth glands, and the total
remissions of all types before the age of 40 constitute 60 per cent. By the age
of 50 years, 80 per cent. of remissions have occurred so that the chances of
obtaining permanent control on stopping carbimazole beyond this age group are
small. Remissions among nodular glands form a small constant fraction of the
total remissions from the age of 30 years onwards. The cases in which there
was no glandular enlargement are relatively few. They appear, however, to give
a peak of incidence in the 50-60 age group and 5 out of the 7 cases have had
remissions of 6, 8, 20, 28, and 29 months respectively. The incidence of remission
in even this small group of patients is high and the impression is that they behave
more like smooth glands in their good response and long remission on carbimazole.
In order to explore further any factors which might possibly relate themselves
numerically, scatter diagrams were drawn against the factors shown in Fig. 6.
It was clear from these diagrams that there was no obvious relationship. Goodwin,
et.al. (1954), in a statistical analysis of the long-term treatment of thyrotoxicosis
with thiouracil compounds were unable to find a significant relationship between
age, length of illness, length of treatment before the drug was withdrawn and
the length of remission obtained in 94 patients. They concluded that other factors
such as intercurrent infection and social maladjustment as suggested by Douglas
and Kennie (1952) might be more important in determining a patient's response
on withdrawing thiouracil treatment. It seems likely that this is so. The complex
endocrine and other aetiological factors and the influence of the psychological
aspect and "make up" of the sufferer undoubtedly play their part. It is, therefore,
not surprising that no statistical connections can be found.
The present study supports the observation that young patients with primary
thyrotoxicosis are most likely to have a satisfactory remission on carbimazole.
Diminution of exophthalmos and gland size or absence of aggravation of these
features are more common in remitting cases.'Weight gain indicates immediate
improvement but is of no prognostic importance regarding duration or
permanency of remission. It cannot be related quantitatively to the initial weight
taken as an index of weight loss, the duration of treatment till euthyroid, nor
to the total amount of carbimazole given till symptoms are controlled. Weight
gain is further unrelated to the 131 T factor, using it as indicative of the severity
of the hyperthyroidism. There is no evidenit relationship between the amount of
weight gained and the stage of relapse for any gland type.
161SUMMARY.
A series of 60 thyrotoxic patients was studied, of which 40 were treated on
carbimazole and thyroxine. Two patients proved resistant. Six to eight months
were required to render the patients euthyroid. Remissions of 5-30 months
occurred in 62.5 per cent. of cases and 76 per cent. of the smooth glands remitted.
The majority of relapses arose within a year.
The effect of treatment on the eye signs, gland size and consistency, body
weight and associated pregnancy are recorded. Toxic complications arose in
4 patients, including 1 with agranulocytic angina with recovery. The occurrence
of contact dermatitis to the tablet is described.
Factors related to the anti-thyroid effect are discussed. No relationship could
be found in regard to age, duration of symptoms, II,, T factor, initial weight of
patient, percentage or actual weight gain, duration of treatment or total quantity
of carbimazole till euthyroid, total length of treatment given and the stage of
relapse.
The following facts emerge:-
1. Carbimazole is a potent anti-thyroid drug with a very low toxic risk.
2. Age and gland type are the most important factors in selection of cases for
treatment, young subjects with smooth glands giving most remissions.
3. In the few cases available for study, those without clinical thyroid enlarge-
ment appear to respond as well as smooth cases in spite of their later age
of presentation.
4. Weight gain occurs in all cases and is variable.
5. Remission is unlikely in cases where the eye changes are aggravated or the
gland enlarges in spite of added thyroxine.
6. Certain resistant cases occur. They constituted 3 per cent. of the series.
The reason for the resistance is obscure.
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REVIEWS
CLINICAL CHEMISTRY IN PRACTICAL MEDICINE. By C. P. Stewart, M.Sc., Ph.D.,
and D. M. Dunlop, M.D., F.R.C.P. Fifth Edition. (Pp. 350; figs. 30. 27s. 6d.) London
and Edinburgh: E. & S. Livingstone, 1958.
THIS edition will maintain this book in its pre-eminent position as a text which should be
read by all medical men who seek to use biochemical data, as well as all those who work
to provide the data.
CARCINOMA OF THE LUNG. Edited by J. R. Bignall, M.D., M.R.C.P. (Volume 1 of
Neoplastic Disease at Various Sites.) (Pp. xii+298; figs. 62; tables 69. 55s.) Edinburgh
and London: E. & S. Livingstone, 1958.
ALL interested in lung cancer will find something of interest in this volume, which, though
the product of eight contributors, maintains a balanced presentation without overlapping.
It ranges from analysis of mortality trends by Case, itiological consideration by Doll,
pathology and laboratory diagnosis by Hinson, through clinical considerations by Bignall,
surgery by Cleland, and radiotherapy by Smithers to chemotherapy by Galton and Papac.
The literature is everywhere documented in detail. The book is a review which must remain
for many years the standard source of reference.
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